Assessment of Health Economics in Alzheimer’s Disease (AHEAD)Treatment with Galantamine in Sweden

被引：0
|
作者：
Frances B. Garfield
Denis Getsios
J. Jaime Caro
Anders Wimo
Bengt Winblad
机构：
[1] Caro Research Institute,Division of General Internal Medicine, Royal Victoria Hospital
[2] Caro Research,Division of Geriatric Medicine
[3] McGill University,undefined
[4] Neurotec,undefined
[5] Karolinska Institutet,undefined
来源：
PharmacoEconomics | 2002年 / 20卷
关键词：
Nursing Home; Rivastigmine; Tacrine; Galantamine; Nursing Home Care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Like other developed countries with aging populations, Sweden is expecting large increases in the prevalence of Alzheimer’s disease and corresponding escalations in the cost of care for patients with this disease. Galantamine, a new acetylcholinesterase inhibitor and nicotinic modulator, has proved effective in managing patients with Alzheimer’s disease in clinical trials.
引用
收藏
页码：629 / 637
页数：8
相关论文
共 50 条
  • [31] A Naturalistic Study of Galantamine for Alzheimer’s Disease
    Henry Brodaty
    Michael Woodward
    Karyn Boundy
    Nicola Barnes
    Gabrielle Allen
    CNS Drugs, 2006, 20 : 935 - 943
  • [32] Galantamine hydrobromide: An agent for Alzheimer's disease
    Zarotsky, V
    Sramek, JJ
    Cutler, NR
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (05) : 446 - 452
  • [33] FDA approves galantamine for Alzheimer's disease
    不详
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2001, 58 (08) : 649 - 649
  • [34] Health economics and the value of therapy in Alzheimer's disease
    Schwam, Elias M.
    Abu-Shakra, Susan
    del Valle, Megan
    Townsend, Raymond J.
    Carrillo, Maria C.
    Fillit, Howard
    ALZHEIMERS & DEMENTIA, 2007, 3 (03) : 143 - 151
  • [35] Ahead of Alzheimer's disease
    Vannini, Patrizia
    LANCET NEUROLOGY, 2021, 20 (08): : 604 - 604
  • [36] Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine
    Nieoullon, Andre
    Bentue-Ferrer, Daniele
    Bordet, Regis
    Tsolaki, Magda
    Foerstl, Hans
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (12) : 3357 - 3367
  • [37] Switching, strategy with galantamine in the treatment of patients with mild to moderate Alzheimer's disease
    Hwang, T-Y.
    Ahn, I-S.
    Yun, J.
    Kim, S.
    Kim, D. K.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 172 - 172
  • [38] The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer's Disease
    Ohnishi, Takashi
    Sakiyama, Yojiro
    Okuri, Yuichi
    Kimura, Yuji
    Sugiyama, Nami
    Saito, Takayuki
    Takahashi, Masayoshi
    Kobayashi, Takumi
    CURRENT ALZHEIMER RESEARCH, 2014, 11 (02) : 110 - 118
  • [39] Four-year safety and efficacy of galantamine in the treatment of Alzheimer's disease
    Burns, A.
    Pirttila, T.
    Gold, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 42 - 43
  • [40] ANALYSIS OF THE EFFECT OF GALANTAMINE IN THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE (AD)
    Moruzzi, E.
    EUROPEAN PSYCHIATRY, 2012, 27
12345